Chris Garabedian

Investor · Perceptive Advisors · Boston, United States

Email

Verified, deliverable email

CEO, Xontogeny and Portfolio Manager, PXV Fund

Stages: Series A
Sectors: Health tech
Cheque size: €92k–€9.2M
Location: Boston, United States
Freshness: Verified today

Notable investments

Zucara TherapeuticsSeries B · $20M · 2024
Marea TherapeuticsSeries B · $190M · 2024
CereVascSeries B · $70M · 2024
Delve BioSeries A · $35M · 2023
Tellus TherapeuticsSeries A · $35M · 2022
Peroxitech TherapeuticsSeries A · $25M · 2022
PolyCore TherapeuticsSeed · $500K · 2022
VivoSenseSeries A · $25M · 2022

Frequently co-invests with

Aaron RoystonvenBioAnthony Philippakis (GV (Google Ventures))Charles HomcyThird Rock VenturesJeffrey TongThird Rock VenturesMaha KatabiSofinnova Investments

Related lists

Health tech investors Series A Health tech in United States

Similar investors

Richard WellsManaging Director, Insight Partners

Ralph (Chris) ChristoffersenPartner, Morgenthaler Ventures

Reinhard VogtVenture Partner, Dynamk Capital

Raj ParekhGeneral Partner, Advent Life Sciences

Blake PateAnalyst, Bios Partners

Richard LimManaging Partner, Cure Ventures

Every contact is a verified, deliverable email. How Mintround verifies contacts.

Are you Chris Garabedian? Request removal of this listing.